Who Paid My Doc
Indigo Dillard
Nurse Practitioner, Family Desoto, TX Nurse Practitioner
NPI 1558025122 CMS profile 11277568
1110 Bristol Cir, Desoto, TX 75115
General payments
$630
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$45,492
Through program year 2025, Indigo Dillard of Desoto, TX is reported in the CMS Open Payments database as having received $630 across 10 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $45,492 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 63rd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $126 | 2 | |
| 2024 | General | $399 | 6 | |
| 2023 | General | $105 | 2 |
Beside peers
- Indigo Dillard
- Nurse Practitioner, Family median
- Middle half of Nurse Practitioner, Family
- National median
In program year 2025, general payments to Indigo Dillard were reported at $126. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.
Show as a table
| Year | Indigo Dillard | Nurse Practitioner, Family median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $39 | $18–$91 | $163 |
| 2020 | $0 | $32 | $17–$76 | $114 |
| 2021 | $0 | $124 | $35–$379 | $132 |
| 2022 | $0 | $141 | $44–$430 | $149 |
| 2023 | $105 | $154 | $49–$476 | $160 |
| 2024 | $399 | $165 | $51–$504 | $164 |
| 2025 | $126 | $168 | $53–$521 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 64 billing codesPaid by Medicare
$1,239,173
Medicare patients
299
Services billed
73,366
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 68% | |
| Osteoporosis | 42% | |
| Ischemic heart disease | 37% | |
| Depression | 29% | |
| COPD | 28% | |
| Diabetes | 26% | |
| Chronic kidney disease | 24% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, tildrakizumab, 1 mg J3245 | Office | 12 | 1,500 | $159,624 |
| Injection, denosumab, 1 mg J0897 | Office | 68 | 4,380 | $91,719 |
| Injection, inclisiran, 1 mg J1306 | Office | 30 | 8,804 | $83,772 |
| Injection, omalizumab, 5 mg J2357 | Office | 23 | 1,980 | $59,350 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 | Office | 14 | 1,575 | $53,523 |
| Injection, tezepelumab-ekko, 1 mg J2356 | Office | 15 | 3,150 | $44,739 |
| Injection, golimumab, 1 mg, for intravenous use J1602 | Office | 11 | 2,325 | $20,806 |
| Injection, infliximab, excludes biosimilar, 10 mg J1745 | Office | 13 | 690 | $17,263 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
5 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| FASENRA |
|
$126 | — | — |
| BRIUMVI |
|
$110 | — | — |
| KRYSTEXXA |
|
$69 | — | — |
| GAMMAGARD |
|
$67 | — | — |
| HYQVIA |
|
$27 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
10 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Family in Texas
David Weir
Nurse Practitioner, Family · Dallas, TX
Robin Beach
Nurse Practitioner, Family · Houston, TX
April Lopez
Nurse Practitioner, Family · McAllen, TX
Sarah Aguilar
Nurse Practitioner, Family · Houston, TX
Sie Thomas
Nurse Practitioner, Family · Dallas, TX
Anna Castro
Nurse Practitioner, Family · San Antonio, TX
Related records
Nurse Practitioner, Family in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Family
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.